CN109077299A - A kind of Hericium erinaceus composition and the preparation method and application thereof - Google Patents
A kind of Hericium erinaceus composition and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109077299A CN109077299A CN201810835936.4A CN201810835936A CN109077299A CN 109077299 A CN109077299 A CN 109077299A CN 201810835936 A CN201810835936 A CN 201810835936A CN 109077299 A CN109077299 A CN 109077299A
- Authority
- CN
- China
- Prior art keywords
- hericium erinaceus
- parts
- powder
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000000588 Hericium erinaceus Species 0.000 title claims abstract description 94
- 235000007328 Hericium erinaceus Nutrition 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 82
- 229920001353 Dextrin Polymers 0.000 claims abstract description 34
- 239000004375 Dextrin Substances 0.000 claims abstract description 34
- 235000019425 dextrin Nutrition 0.000 claims abstract description 34
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 33
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 29
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 230000000968 intestinal effect Effects 0.000 claims abstract description 16
- 241000222684 Grifola Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000013402 health food Nutrition 0.000 claims abstract description 12
- 230000009854 mucosal lesion Effects 0.000 claims abstract description 10
- 230000001681 protective effect Effects 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 235000013361 beverage Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 8
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 7
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 7
- 229940100688 oral solution Drugs 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007921 spray Substances 0.000 claims description 19
- 240000001080 Grifola frondosa Species 0.000 claims description 15
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 abstract description 7
- 239000003826 tablet Substances 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 abstract 1
- 210000000476 body water Anatomy 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000001156 gastric mucosa Anatomy 0.000 description 13
- 208000005718 Stomach Neoplasms Diseases 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 206010017758 gastric cancer Diseases 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- -1 hydroxy-propyl Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides a kind of Hericium erinaceus compositions and the preparation method and application thereof, belong to food, health food, field of pharmaceutical technology.The Hericium erinaceus composition contains Hericium erinaceus, mushroom, grifola frondosus, further includes resistant dextrin, oligofructose, yeast beta glucan.The composition the preparation method is as follows: weighing raw material by weight；Wherein resistant dextrin, oligofructose, the drying of yeast beta glucan, pulverize, ultra micro coarse powder are made；Hericium erinaceus, mushroom, grifola frondosus raw material are added resistant dextrin, oligofructose, yeast beta glucan ultra micro coarse powder and are uniformly mixed, and pulverize, and Hericium erinaceus composition is made.Solid beverage, tablet, capsule, granule, oral solution can be made in the composition.The composition has the application in protective effect, killing helicobacter pylori, the food for adjusting intestinal flora, health food or drug to mucosal lesion in preparation.
Description
Technical field
The present invention relates to food, health food, field of pharmaceutical technology, in particular to a kind of Hericium erinaceus composition and
Preparation method and application.
Background technique
Stomach is the critical organ that human consumption absorbs, and various foods are required to grinding and and stomach by stomach wall (gastric mucosa)
After the gastric juice effect of mucosal secretions, paste chyme can be become, then enter small intestine and further digest and absorb as nutrition
Substance.Though gastric mucosa has special protective effect, very fragile, environment, diet, drug, smoking, excessive drinking, bacterium sense to stomach
The factors such as dye, emotional change can all damage it.The damage and self-regeneration of gastric mucosa are typically in dynamic equilibrium, but
Once stomach is given in the external world, over-burden or stimulation is too strong, and dynamic equilibrium will be broken, and is difficult to restore again after gastric mucosa is impaired,
It is followed by that the symptom of series of gastric discomfort, common are epigastric discomfort or pain, nausea,vomiting,diarrhea, food
It is intended to depressed etc..
The integrality of the principle normal gastric mucosa of gastric mucosa damage be by the dynamic equilibrium of attack factor and defense factor Lai
It maintains, once this balance is destroyed, it will lead to the damage of gastric mucosa.By taking ethyl alcohol as an example, ethyl alcohol causes gastric mucosa damage can
It can generate excessive with intracellular calcium overload, oxygen radical and cause cell membrane fluidity decline related, ethyl alcohol can activate gastric mucosa
Mast cell makes it discharge histamine, blood platelet activation factor (PAF), Endothelin, leukotriene and various superoxides, wherein group
Amine, PAF can increase gastric mucosa permeability, and Endothelin, leukotriene can enhance gastric mucosa to the sensibility of damage, meanwhile, ethyl alcohol is also
Stomach can be stimulated to move, make to squeeze blood vessel when contraction of muscle, cause ischaemic, reduce gastric mucosal blood flow, to influence stomach
Mucous membrane is normally metabolized and function, weakens the ability of its antibody Monoclonal and reparation, eventually leads to gastric mucosa damage.
It is found and separation by Warren and Marshall for the first time from nineteen eighty-two, oneself confirmed, pylorus of the research over more than 30 years
The infection of helicobacter (Helicobacterpylori, Hp) and chronic active gastritis, peptic ulcer, gastric cancer,
The generation of stomach MALT lymthoma is closely related, is to cause the arch-criminal of peptic ulcer and chronic active gastritis, and stomach is burst
Ulcer and atrophic gastritis may develop into gastric cancer again.
The generation of most of gastric cancers may be after following procedure: superficial gastritis arrives intestinal metaplasia to atrophic gastritis again
Or dysplasia, gastric cancer.A large amount of epidemiological survey data also indicates that, in the higher area of incidence gastric cancer rate, the infection of Hp
Rate is also relatively high.
Foreign medical science expert once carried out a follow, right using the data for the healthy population Serum Bank that one's early years collect
There is provided serum person carried out long term follow-up, by among them after serum is provided 6~14 years patients for having suffered from gastric cancer with mention simultaneously
For serum, age, gender is suitable and does not obtain the Healthy People of gastric cancer and contrasts.It was found that anti-Hp antibody positive in the serum of gastric cancer person
Rate (positive indicates Hp infection) is significantly higher than, and gastric cancer person does not occur.The risk that Hp infection can be such that gastric cancer occurs increases by 3~6
Times.
Intestinal flora and human body establish close relationship in very long evolution, are not only to have opposed but also unified therebetween
Unity of contradictions body.By long-term natural selection process, intestinal flora and human body have reached a kind of mutual reciprocity and mutual benefit and mutual system
Metastable dynamic balance state about.Human body provides living space for flora and energy source, flora then help human body
It synthesizes some nutrients and directly or indirectly influences the physiological function of human body.
Many experiments confirm that intestinal flora divides the growth of the normal metabolic activity of human body, nutrient absorption, epithelial cell
Change, the immune response of normal bowel mucous membrane is formed and maintained etc. and plays the role of very important, while they and certain diseases
Disease also has a closely connection, including the lienterics such as abdominal distension abdominal pain disease, inflammatory bowel disease, cancer, Multiple Organ are disorderly
Disorderly, allergy etc..
Intestinal flora not only influences the digestion and absorption of food, also affects the absorption and metabolism of oral drugs.Therefore,
Intestinal flora can all have an impact the metabolism of drug and therapeutic effect, it is also possible to the original of drug therapy generation individual difference
One of because.
Lacking currently on the market not only had protective effect to mucosal lesion, but also can kill helicobacter pylori, can also adjust
Food, health food or the drug of intestinal flora.
Summary of the invention
The first aspect of the present invention is designed to provide a kind of Hericium erinaceus composition.
A kind of preparation method for being designed to provide above-mentioned Hericium erinaceus composition of the second aspect of the present invention, this method are logical
Ultramicro crushing treatment is crossed, utilization rate is improved, so that the better effect of the Hericium erinaceus composition.
A kind of application for being designed to provide above-mentioned Hericium erinaceus composition of the third aspect of the present invention, i.e., above-mentioned Hericium erinaceus
Composition preparation to mucosal lesion have protective effect and/or kill helicobacter pylori and/or adjust intestinal flora food,
Application in health food or drug.
In order to realize above-mentioned purpose of the invention, the following technical scheme is adopted:
A kind of Hericium erinaceus composition, contains Hericium erinaceus, mushroom, grifola frondosus.
Further, which further includes resistant dextrin and/or oligofructose and/or yeast beta glucan.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Wherein resistant dextrin and/or oligofructose and/or the drying of yeast beta glucan, Ultramicro-powder
It is broken, ultra micro coarse powder is made；Hericium erinaceus, mushroom, Grifola Frondosa sporophore Ultramicro-powder or fructification water extract spray powder or fructification water
Resistant dextrin and/or oligofructose is added for extract freeze-dried powder or fructification water extract extract powder and/or yeast beta glucan ultra micro is thick
Powder is uniformly mixed, and is pulverized, and Hericium erinaceus composition is made.
Oral system can be made in the Hericium erinaceus composition and food, health food or pharmaceutically acceptable carrier or auxiliary material
Agent.
Said preparation can be solid beverage, tablet, capsule, granule, oral solution.
The Hericium erinaceus composition has protective effect to mucosal lesion in preparation and/or kills helicobacter pylori and/or tune
Application in the food of whole intestinal flora, health food or drug.
Compared with prior art, the beneficial effect of present disclosure includes:
This Hericium erinaceus composition and this preparation that present disclosure provides, than the Hericium erinaceus of independent parts by weight,
Mushroom, grifola frondosus, resistant dextrin, oligofructose, yeast beta glucan have protective effect to mucosal lesion and/or kill pylorus
Helicobacter and/or the better effect for adjusting intestinal flora.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is
The conventional products that can be obtained by commercially available purchase.
Present embodiment provides a kind of Hericium erinaceus composition, contains Hericium erinaceus, mushroom, grifola frondosus.
Further, according to parts by weight, Hericium erinaceus composition is according to parts by weight, fragrant containing 30~70 parts of Hericium erinaceus
5~15 parts of mushroom, 5~15 parts of grifola frondosus.
Further, which further includes resistant dextrin and/or oligofructose and/or yeast beta glucan.
Further, the Hericium erinaceus composition, according to parts by weight, containing 30~70 parts of Hericium erinaceus, mushroom 5~15
Part, 5~15 parts of grifola frondosus, 10~30 parts of resistant dextrin, 10~30 parts of oligofructose, 2~8 parts of yeast beta glucan.
Preferably, the Hericium erinaceus composition, according to parts by weight, containing 50 parts of Hericium erinaceus, 10 parts of mushroom, grifola frondosus 10
Part, 20 parts of resistant dextrin, 20 parts of oligofructose, 5 parts of yeast beta glucan.
The Hericium erinaceus composition, it is super that Hericium erinaceus, mushroom, grifola frondosus raw material can be Hericium erinaceus, mushroom, Grifola Frondosa sporophore
Micro mist or fructification water extract spray powder or fructification water extract freeze-dried powder or fructification water extract extract powder.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Wherein resistant dextrin and/or oligofructose and/or the drying of yeast beta glucan, -10
5min is pulverized at DEG C, and ultra micro coarse powder is made；Hericium erinaceus, mushroom, Grifola Frondosa sporophore Ultramicro-powder or the spray of fructification water extract
Resistant dextrin and/or oligofructose and/or ferment is added in dry powder or fructification water extract freeze-dried powder or fructification water extract extract powder
Female beta glucan ultra micro coarse powder is uniformly mixed, and pulverizes 20min at -25 DEG C, and Hericium erinaceus composition is made.
Present embodiment also provides a kind of preparation, which includes that above-mentioned Hericium erinaceus composition and food, health care are eaten
Oral preparation can be made in product or pharmaceutically acceptable carrier or auxiliary material.
Said preparation can be solid beverage, tablet, capsule, granule, oral solution.
Herein, term " food, health food or pharmaceutically acceptable " refers to the chemical combination when compound is to human administration
Object is physiologically acceptable, and the allergic reactions such as gastrointestinal disturbance, dizziness or anaphylactoid similar to these will not occur
Systemic anaphylaxis.
In the present invention, " food, health food or pharmaceutically acceptable carrier or auxiliary material " includes but is not limited to: bonding
Agent (such as microcrystalline cellulose, alginates, gelatin and polyvinylpyrrolidone), filler (such as starch, sucrose, glucose and anhydrous
Lactic acid), disintegrating agent (such as cross-linked pvp, crosslinked carboxymethyl fecula sodium, croscarmellose sodium and low substituted hydroxy-propyl fiber
Element), lubricant (magnesium stearate, aluminum stearate, talcum, polyethylene glycol, sodium benzoate), wetting agent (such as glycerol), surface-active
Agent (such as hexadecanol) and sorbefacient, corrigent, sweetener, diluent, coating agent.
Present embodiment also provide a kind of above-mentioned Hericium erinaceus composition preparation to mucosal lesion have protective effect and/or
Kill the application in the food, health food or drug of helicobacter pylori and/or adjustment intestinal flora.
This Hericium erinaceus composition and this preparation that present disclosure provides, than the Hericium erinaceus of independent parts by weight,
Mushroom, grifola frondosus, resistant dextrin, oligofructose, yeast beta glucan have protective effect to mucosal lesion and/or kill pylorus
Helicobacter and/or the better effect for adjusting intestinal flora.
Feature and performance of the invention are described in further detail with reference to embodiments:
Embodiment 1
The present embodiment provides a kind of Hericium erinaceus compositions comprising:
Hericium erinaceus fruiting body Ultramicro-powder 300g, mushroom fruiting body water extract spray powder 150g, Grifola Frondosa sporophore water extract
Freeze-dried powder 50g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Hericium erinaceus fruiting body Ultramicro-powder, mushroom fruiting body water extract spray powder, ash tree beggar are real
Body water extract freeze-dried powder is uniformly mixed, and pulverizes 20min at -25 DEG C, and Hericium erinaceus composition is made.
Embodiment 2
The present embodiment provides a kind of Hericium erinaceus compositions comprising:
Hericium erinaceus fruiting body water extract extract powder 700g, mushroom fruiting body water extract freeze-dried powder 50g, Grifola Frondosa sporophore water
Extract spray powder 150g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Hericium erinaceus fruiting body water extract extract powder, mushroom fruiting body water extract freeze-dried powder, ash tree
Beggar's entity water extract spray powder is uniformly mixed, and pulverizes 20min at -25 DEG C, and Hericium erinaceus composition is made.
Embodiment 3
The present embodiment provides a kind of Hericium erinaceus compositions comprising:
Hericium erinaceus fruiting body water extract freeze-dried powder 500g, mushroom fruiting body water extract spray powder 100g, Grifola Frondosa sporophore
Ultramicro-powder 100g, resistant dextrin 100g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；It wherein dries 3 hours for 60 DEG C of resistant dextrin, pulverizes 5min at -10 DEG C, be made
Ultra micro coarse powder；Hericium erinaceus fruiting body water extract extract powder, mushroom fruiting body water extract spray powder, Grifola Frondosa sporophore Ultramicro-powder add
Enter resistant dextrin ultra micro coarse powder to be uniformly mixed, pulverize 20min at -25 DEG C, Hericium erinaceus composition is made.
Embodiment 4
Hericium erinaceus fruiting body Ultramicro-powder 500g, mushroom fruiting body water extract freeze-dried powder 100g, Grifola Frondosa sporophore extract powder
100g, resistant dextrin 300g, oligofructose 100g, yeast beta glucan 80g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Wherein resistant dextrin, oligofructose and yeast beta glucan are small respectively at 60 DEG C of drying 3
When, 5min is pulverized at -10 DEG C, ultra micro coarse powder is made；Hericium erinaceus fruiting body water extract extract powder, mushroom fruiting body water mention
It is equal that resistant dextrin, oligofructose and the mixing of yeast beta glucan ultra micro coarse powder is added in object spray powder, Grifola Frondosa sporophore Ultramicro-powder
It is even, 20min is pulverized at -25 DEG C, Hericium erinaceus composition is made.
Embodiment 5
Hericium erinaceus fruiting body water extract freeze-dried powder 500g, mushroom fruiting body water extract spray powder 100g, Grifola Frondosa sporophore
Ultramicro-powder 100g, resistant dextrin 200g, oligofructose 300g, yeast beta glucan 20g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Wherein resistant dextrin, oligofructose and yeast beta glucan are small respectively at 60 DEG C of drying 3
When, 5min is pulverized at -10 DEG C, ultra micro coarse powder is made；Hericium erinaceus fruiting body water extract extract powder, mushroom fruiting body water mention
It is equal that resistant dextrin, oligofructose and the mixing of yeast beta glucan ultra micro coarse powder is added in object spray powder, Grifola Frondosa sporophore Ultramicro-powder
It is even, 20min is pulverized at -25 DEG C, Hericium erinaceus composition is made.
Embodiment 6
Hericium erinaceus fruiting body water extract spray powder 500g, mushroom fruiting body water extract extract powder 100g, Grifola Frondosa sporophore
Water extract freeze-dried powder 100g, resistant dextrin 200g, oligofructose 200g, yeast beta glucan 50g.
The preparation method of the Hericium erinaceus composition, comprising the following steps:
Raw material is weighed by weight；Wherein resistant dextrin, oligofructose and yeast beta glucan are small respectively at 60 DEG C of drying 3
When, 5min is pulverized at -10 DEG C, ultra micro coarse powder is made；Hericium erinaceus fruiting body water extract freeze-dried powder, mushroom fruiting body water mention
Object extract powder, Grifola Frondosa sporophore water extract spray powder are added resistant dextrin, oligofructose and yeast beta glucan ultra micro coarse powder and mix
It closes uniformly, pulverizes 20min at -25 DEG C, Hericium erinaceus composition is made.
Embodiment 7
The present embodiment provides a kind of solid beverages:
It takes appropriate 70% alcohol to be uniformly mixed with 6 Hericium erinaceus composition of above-described embodiment, crosses 20 meshes, whole grain is dried, often
Solid beverage is made in bag 10g, packaging.
Embodiment 8
Appropriate amount of starch, dextrin is added in 6 Hericium erinaceus composition of above-described embodiment, is uniformly mixed, and particle is made, and tabletting is wrapped thin
Film clothing is to get tablet.
Embodiment 9
The present embodiment provides a kind of capsule, the preparation method of the capsule includes:
Appropriate amount of starch, dextrin is added in 6 Hericium erinaceus composition of above-described embodiment, mixes, and particle is made, and is packed into hard capsule, i.e.,
Obtain capsule.
Embodiment 10
The present embodiment provides a kind of granule, the preparation method of the granule includes:
Appropriate amount of starch, dextrin is added in 6 Hericium erinaceus composition of above-described embodiment, mixes, wet granulation, whole grain after drying, packet
Dress is to get granule.
Comparative example 1~6 (i.e. hericium erinaceus fruiting body water extract spray powder, mushroom fruiting body water extract extract powder, ash tree beggar
Entity water extract freeze-dried powder, resistant dextrin, oligofructose, yeast beta glucan) experiment with sample the preparation method is as follows:
Raw material is weighed, is dried 3 hours respectively at 60 DEG C, 5min is pulverized at -10 DEG C, ultra micro coarse powder is made；- 25
20min is pulverized at DEG C, and sample is made.
Note: 20min directly is being pulverized at -25 DEG C after freeze-dried powder, object extract powder, spray powder drying, sample is made.
Experimental example 1
To ethyl alcohol cause gastric mucosa damage protective effect choose healthy SD rat, half male and half female, weight 180~
220g is randomly divided into control group, Examples 1 to 10 group, hericium erinaceus fruiting body water extract spray powder, the leaching of mushroom fruiting body water extract
Cream powder, Grifola Frondosa sporophore water extract freeze-dried powder, resistant dextrin, oligofructose, yeast beta glucan group, totally 17 groups, every group 10
Animal.In addition to control group, number is 1~16 group respectively in order.Daily gastric infusion 1 time, dosage is 2000mg/kg, even
Continuous 7d, control group give equal amount of distilled water.Before experiment, rat elder generation fasting 48h, free water, greatly in 1h every after the last administration
Mouse stomach-filling dehydrated alcohol 1mL/ only, after 1h cervical dislocation puts to death animal, closes cardia with clip folder, injects 1% formaldehyde from pylorus
5mL, then press from both sides and close pylorus, it is put into the fixed 10min of 1% formalin, stomach wall is cut off along greater curvature, measures damaged length, with damage
Length (width is doubled greater than 1mm) summation calculates inhibiting rate as gastric mucosal damage index.
Inhibiting rate (%)=(control group ulcer index-administration group ulcer index)/control group ulcer index × 100%
Table 1 to the influence experimental result of rat acute mucosal lesion caused by ethyl alcohol (N=10)
| Serial number | Group | Ulcer index (mm) |
| 1 | Control group | 95.1±28.9 |
| 2 | 1st group | 51.5±21.9 |
| 3 | 2nd group | 50.1±20.7 |
| 4 | 3rd group | 45.2±21.6 |
| 5 | 4th group | 42.5±20.9 |
| 6 | 5th group | 41.1±17.9 |
| 7 | 6th group | 38.1±17.1 |
| 8 | 7th group | 38.9±18.2 |
| 9 | 8th group | 39.7±19.5 |
| 10 | 9th group | 39.5±19.7 |
| 11 | 10th group | 39.1±17.5 |
| 12 | 11st group | 55.1±21.9 |
| 13 | 12nd group | 58.5±22.7 |
| 14 | 13rd group | 57.2±23.6 |
| 15 | 14th group | 58.5±23.9 |
| 16 | 15th group | 62.1±25.1 |
| 17 | 16th group | 60.1±23.2 |
As shown in Table 1, compared with control group and 1~6 group of comparative example, Examples 1 to 10 group is especially Examples 1 to 10 group
6~10 groups of embodiment have a clear superiority to the recovery extent of rat acute mucosal lesion caused by ethyl alcohol.
Experimental example 2
By clinical trial, pharmaceutical composition of the invention is demonstrated to upper digestive tract caused by helicobacter pylori infections
Disease has good curative effect, and test method and result are as follows.
1. diagnostic criteria
Diagnostic criteria in 2016 " the 5th national helicobacter pylori infections processing common recognition report ".
2. clinical data
Choose the 10 progress clinical observations of patient for meeting above-mentioned diagnostic criteria.
3. treatment method
Treatment group: giving solid beverage made by the pharmaceutical composition of the present invention of embodiment 7, and 1 bag every time (10g dress), often
Day 2 times.
The course for the treatment of is 15 days, is checked after treatment end13C urea breath test.
Criterion of therapeutical effect
It cures:13The result of C urea breath test is feminine gender.
It is invalid:13The result of C urea breath test is the positive.
5. treatment results
Control group: curing 8, and effective percentage 80% has no adverse reaction.
Experimental example 3
Human experimentation method
Experimenter's mass selection is selected in nearly one month and was not suffering from gastrointestinal disease, does not take antibiotic, age 20~65 years old, physical examination refers to
The whole normal volunteers 20 of mark.
Volunteer is randomly divided into experimental group and control group, every group of 10 people, men and women is fifty-fifty.
Experimental method
Experimental group takes the Hericium erinaceus composition that the obtained tool of embodiment 6 adjusts intestinal flora function.Control group takes sugarcane
Sugar.Experimental group and control group instructions of taking are each 10g 2 times a day, are continuously taken 15 days.It is responsible for sending out sample simultaneously by special messenger
Supervision is taken, and does not change original eating habit, normal diet during test.Test group and each control group are taking tested material
It is preceding and continuously take tested material 15 days after, respectively aseptic collection excrement carry out 10 times be serially diluted, select suitable dilution,
Be seeded on various culture mediums, cultivated as required respectively, then to culture carry out bacterium colony (Bifidobacterium, lactobacillus and
Produce gas and press from both sides film bacillus) it counts.
2 human experiment group of table foretastes front and back flora situation and compares (cfu/g)
As shown in Table 2, compared with the control group, experimental group crowd tool obtained by edible embodiment 6 adjusts intestinal flora
After the Hericium erinaceus composition of function, the quantity of Bifidobacterium and lactobacillus is dramatically increased, and C.perfringens quantity significantly reduces.
Above-mentioned human trial shows: the present invention, which has the lactic bacteria composition for adjusting intestinal flora function, has adjusting enterobacteriaceae
The effect of group's balance.
In addition, Hericium erinaceus composition, solid beverage, tablet, capsule or granule that other embodiments are provided etc. are used
In carrying out above-mentioned experiment, test result is similar to the above results, therefore does not repeat one by one.
Although illustrate and describing the present invention with specific embodiment, it will be appreciated that without departing substantially from of the invention
Many other change and modification can be made in the case where spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of Hericium erinaceus composition, which is characterized in that the Hericium erinaceus composition contains Hericium erinaceus, mushroom, grifola frondosus.
2. Hericium erinaceus composition according to claim 1, which is characterized in that the Hericium erinaceus composition further includes resistance paste
Essence and/or oligofructose and/or yeast beta glucan.
3. Hericium erinaceus composition according to claim 2, which is characterized in that according to parts by weight, the Hericium erinaceus 30~
70 parts, 5~15 parts of the mushroom, 5~15 parts of the grifola frondosus.
4. Hericium erinaceus composition according to claim 2, which is characterized in that according to parts by weight, the Hericium erinaceus 30~
70 parts, 5~15 parts of the mushroom, 5~15 parts of the grifola frondosus, 10~30 parts of the resistant dextrin, the oligofructose 10~
30 parts, 2~8 parts of the yeast beta glucan.
5. Hericium erinaceus composition according to claim 2, which is characterized in that according to parts by weight, 50 parts of the Hericium erinaceus,
10 parts of the mushroom, 10 parts of the grifola frondosus, 20 parts of the resistant dextrin, 20 parts of the oligofructose, the yeast beta glucan
5 parts.
6. Hericium erinaceus composition according to claim 5, characterized in that it comprises: the Hericium erinaceus, mushroom, ash tree
Flower is fructification Ultramicro-powder or fructification water extract spray powder or fructification water extract freeze-dried powder or fructification water extract extract powder.
7. a kind of preparation method of Hericium erinaceus compositions described in any item according to claim 1~6, which is characterized in that including
Following steps:
According to claim 1 ,~5 any parts by weight weigh raw material；Resistant dextrin and/or oligofructose and/or yeast β
Glucan drying, pulverizes 5min at -10 DEG C, and ultra micro coarse powder is made；Hericium erinaceus, mushroom, Grifola Frondosa sporophore Ultramicro-powder
Or fructification water extract spray powder or fructification water extract freeze-dried powder or fructification water extract extract powder be added resistant dextrin and/or
Oligofructose and/or yeast beta glucan ultra micro coarse powder are uniformly mixed, and pulverize 20min at -25 DEG C, and Hericium erinaceus group is made
Close object.
8. a kind of preparation, which is characterized in that the preparation include the described in any item Hericium erinaceus compositions of claim 1~6 with
Food, health food or pharmaceutically acceptable carrier or auxiliary material.
9. preparation according to claim 8, which is characterized in that the preparation include solid beverage, tablet, capsule,
Granula, oral solution.
10. a kind of Hericium erinaceus composition as described in claim 1~6 preparation to mucosal lesion have protective effect and/or
Kill the application in the food, health food or drug of helicobacter pylori and/or adjustment intestinal flora.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810835936.4A CN109077299A (en) | 2018-07-26 | 2018-07-26 | A kind of Hericium erinaceus composition and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810835936.4A CN109077299A (en) | 2018-07-26 | 2018-07-26 | A kind of Hericium erinaceus composition and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109077299A true CN109077299A (en) | 2018-12-25 |
Family
ID=64830919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810835936.4A Pending CN109077299A (en) | 2018-07-26 | 2018-07-26 | A kind of Hericium erinaceus composition and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109077299A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110897162A (en) * | 2019-11-26 | 2020-03-24 | 浙江省农业科学院 | Stomach-protecting composition and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744846A (en) * | 2009-12-25 | 2010-06-23 | 福州汉方生物技术有限公司 | Edible mycotic composite amylase nutritional agent |
| CN102488278A (en) * | 2011-12-08 | 2012-06-13 | 北京东方兴企食品工业技术有限公司 | Composite fungus nutrient solution with bifunctional health care effect |
| CN105055438A (en) * | 2015-07-21 | 2015-11-18 | 珲春市神怡菌业生物科技开发有限公司 | Lentinan prebiotic composition with gastrointestinal tract function improving effect |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN105495621A (en) * | 2015-12-17 | 2016-04-20 | 重庆希尔安药业有限公司 | Health-care food used for protecting liver and stomach and preparation method thereof |
| CN107232610A (en) * | 2017-05-25 | 2017-10-10 | 杭州特悘衡康生物科技有限公司 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
| CN107751703A (en) * | 2017-11-28 | 2018-03-06 | 广东君道营养科技有限公司 | A kind of solid beverage and its detection method with regulation gut flora function |
| CN108030082A (en) * | 2017-12-28 | 2018-05-15 | 内蒙古蒙合利生物有限公司 | A kind of nourishing the stomach and the edible mushroom oral liquid of regulating gastointestinal function |
-
2018
- 2018-07-26 CN CN201810835936.4A patent/CN109077299A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744846A (en) * | 2009-12-25 | 2010-06-23 | 福州汉方生物技术有限公司 | Edible mycotic composite amylase nutritional agent |
| CN102488278A (en) * | 2011-12-08 | 2012-06-13 | 北京东方兴企食品工业技术有限公司 | Composite fungus nutrient solution with bifunctional health care effect |
| CN105055438A (en) * | 2015-07-21 | 2015-11-18 | 珲春市神怡菌业生物科技开发有限公司 | Lentinan prebiotic composition with gastrointestinal tract function improving effect |
| CN105454966A (en) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | Probiotics solid beverage for improving gastrointestinal tract and immunity and preparation method thereof |
| CN105495621A (en) * | 2015-12-17 | 2016-04-20 | 重庆希尔安药业有限公司 | Health-care food used for protecting liver and stomach and preparation method thereof |
| CN107232610A (en) * | 2017-05-25 | 2017-10-10 | 杭州特悘衡康生物科技有限公司 | A kind of carbohydrate composition of beta glucan containing yeast and its application |
| CN107751703A (en) * | 2017-11-28 | 2018-03-06 | 广东君道营养科技有限公司 | A kind of solid beverage and its detection method with regulation gut flora function |
| CN108030082A (en) * | 2017-12-28 | 2018-05-15 | 内蒙古蒙合利生物有限公司 | A kind of nourishing the stomach and the edible mushroom oral liquid of regulating gastointestinal function |
Non-Patent Citations (1)
| Title |
|---|
| 刘蓝天等: "酵母β-葡聚糖的研究进展及应用", 《食品工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110897162A (en) * | 2019-11-26 | 2020-03-24 | 浙江省农业科学院 | Stomach-protecting composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101384700B (en) | Novel lactobacillus strains and their use against helicobacter pylori | |
| CN1663573B (en) | A stable and safe microecological formulation, its preparation and usage | |
| CN103190626B (en) | Fruit and vegetable food for treating oral ulcer and preparation method of fruit and vegetable food | |
| CN109666615A (en) | A kind of probiotic composition and its application | |
| CN104366480A (en) | Lipid-lowering and weight-reducing nutritional meal powder and preparation method thereof | |
| CN103749982B (en) | Feed for improving egg yield, traditional Chinese medicine additive and preparation method thereof | |
| CN109628358A (en) | A kind of compound probiotic and its application | |
| CN109528776A (en) | A kind of compound probiotic lozenge of prophylactic treatment mouth disease and preparation method thereof | |
| CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
| CN109846035A (en) | A kind of compound probiotic composition with body weight control | |
| CN110150667A (en) | A kind of health care product and preparation method thereof for promoting immunity and adjusting function of intestinal canal | |
| US20230072816A1 (en) | Method To Improve The Health Of The Microbiome In A Human Gastrointestinal System And Multi-Chamber Probiotic Delivery Products Therefor | |
| CN108904546A (en) | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof | |
| CN104738638A (en) | Composition with anti-fatigue effect and application thereof | |
| CN105249480A (en) | Chewable tablet with dietary fiber and bifidobacteria and preparing method thereof | |
| CN102283342B (en) | Functional total-nutrient liquid food for space flight and preparation method thereof | |
| CN109077299A (en) | A kind of Hericium erinaceus composition and the preparation method and application thereof | |
| CN104547769A (en) | Complex fermentation type traditional Chinese medicine for promoting livestock and poultry to gain weight and preparation method for complex fermentation type traditional Chinese medicine | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN102028021A (en) | Female radish (male barren radish) freeze-dried powder | |
| CN110200926A (en) | Composite reactive freeze-dried powder and its preparation method and application | |
| CN102342313A (en) | Cancer-prevention and anticancer green miniature food by industrial production | |
| CN107373192A (en) | One kind improves crucian meat feed | |
| CN107259572A (en) | A kind of puerpera's postpartum nutritious food, postpartum recuperating meal and preparation method thereof | |
| CN111296842B (en) | Probiotic composition with anti-allergy effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |
|
| RJ01 | Rejection of invention patent application after publication |